API | melitracene

melitracene (Melixeran) Report issue

Small molecule Experimental

AACT ChEMBL Drug Central KEGG PubChem

Active Ingredient History

NOW

Melitracen is a tricyclic antidepressant (TCA), for the treatment of depression and anxiety. In addition to single drug preparations, it is also available as Deanxit, marketed by Lundbeck, a combination product containing both melitracen and flupentixol. ^Wikipedia

Chemistry

SMILES: CN(C)CCC=C1c2ccccc2C(C)(C)c2ccccc21
InChIKey: GWWLWDURRGNSRS-UHFFFAOYSA-N
Mol. Mass: 291.44
ALogP: 4.71 Partition coefficient
ChEMBL Molecules:

melitracen

melitracen hydrochloride

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

dixeran | melitracen | melitracene | melitracen hcl | melitracen hydrochloride

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (8)

Approved Indications (1)

Anxiety

Experimental Indications - Clinical Trial Phases 1-4 (7)

Compliance (Phase 4)

Depression (Phase 4)

Dyspepsia (Phase 4)

Globus Sensation (Phase 3)

Healthy Volunteers (Phase 1)

Heart Diseases (Phase 1/Phase 2)

Tinnitus (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue